These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 2213677)
1. The clinical and scientific basis of drug toxicity. A report of a conference. Shah RR; Walley T J R Coll Physicians Lond; 1990 Jul; 24(3):219-23. PubMed ID: 2213677 [No Abstract] [Full Text] [Related]
2. Suspected adverse reactions, 2007. Dyer F; Spagnuolo-Weaver M; Coolees S; Tait A Vet Rec; 2008 Jul; 163(3):69-72. PubMed ID: 18702197 [No Abstract] [Full Text] [Related]
3. Postmarketing surveillance of adverse drug reactions: problems and solutions. Lortie FM CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483 [TBL] [Abstract][Full Text] [Related]
4. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective. Bee JS; Goletz TJ; Ragheb JA J Pharm Sci; 2012 Oct; 101(10):3580-5. PubMed ID: 22736570 [TBL] [Abstract][Full Text] [Related]
5. Pediatric registries at the Food and Drug Administration: design aspects that increase their likelihood of success. Winiecki SK; Tejero-Taldo MI; Avant D; Murphy D; McMahon AW Pharmacoepidemiol Drug Saf; 2016 May; 25(5):602-5. PubMed ID: 26687996 [TBL] [Abstract][Full Text] [Related]
6. Postmarketing safety of biologics and biological devices. Woo EJ Spine J; 2014 Mar; 14(3):560-5. PubMed ID: 24342704 [TBL] [Abstract][Full Text] [Related]
7. Did the drug do it? Grob PR Br Med J (Clin Res Ed); 1986 Sep; 293(6549):757. PubMed ID: 3094642 [No Abstract] [Full Text] [Related]
8. Researching drug treatment. Martys CR Br Med J (Clin Res Ed); 1984 Nov; 289(6455):1353-4. PubMed ID: 6437549 [No Abstract] [Full Text] [Related]
9. Safety issues specific to clinical development of protein therapeutics. Haller CA; Cosenza ME; Sullivan JT Clin Pharmacol Ther; 2008 Nov; 84(5):624-7. PubMed ID: 18701885 [No Abstract] [Full Text] [Related]
10. Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. DiMartino LD; Curtis LH; Williams RL; Abernethy DR; Schulman KA Food Drug Law J; 2008; 63(4):891-900. PubMed ID: 19601387 [No Abstract] [Full Text] [Related]
11. Taking immunogenicity assessment of therapeutic proteins to the next level. Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596 [TBL] [Abstract][Full Text] [Related]
15. Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules. Ebbers HC; Al-Temimi E; Moors EH; Mantel-Teeuwisse AK; Schellekens H; Leufkens HG BioDrugs; 2013 Apr; 27(2):167-74. PubMed ID: 23400874 [TBL] [Abstract][Full Text] [Related]
16. The importance of postmarketing drug surveillance. Smart AJ; Walters L S Afr Med J; 1992 Dec; 82(6):383-4. PubMed ID: 1465681 [No Abstract] [Full Text] [Related]
17. Why do doctors not report adverse drug reactions? Leiper JM; Lawson DH Neth J Med; 1985; 28(12):546-50. PubMed ID: 3911083 [No Abstract] [Full Text] [Related]
18. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products. Marszal E; Fowler E J Pharm Sci; 2012 Oct; 101(10):3555-9. PubMed ID: 22736535 [TBL] [Abstract][Full Text] [Related]